Comparison

ABBOTT LABORATORIES (ABT) vs ZIMMER BIOMET HOLDINGS, INC. (ZBH)

The same filed metrics for both companies, side by side.

What each names as a risk in its own annual report, how each is priced against its own history, and the tracked managers whose latest 13F reports a position in both.

Financials

ABT

ABBOTT LABORATORIES

Medical Devices

Revenue, FY25: $44.33B
Net income: $6.52B
Operating cash flow: $9.57B
Free cash flow: $7.4B
Net margin: 14.72%
Operating margin: 18.17%
Gross margin: 56.42%

ZBH

ZIMMER BIOMET HOLDINGS, INC.

Medical Devices

Revenue, FY25: $8.23B
Net income: $705M
Operating cash flow: $1.7B
Free cash flow: $1.47B
Net margin: 8.57%
Operating margin: 13.34%
Gross margin: 69.71%

Head-to-head

Filed growth, quality and valuation, read against each company’s own history rather than against the other side.

Metric	ABT	ZBH
Revenue growth, latest filed year	+5.67%	+7.20%
Piotroski F-score	6 of 9	5 of 9
P/E against its own history	15.41% below	11.07% below

What each says it is exposed to

From Item 1A of each company’s most recent 10-K.

ABT

Currency moves
Cybersecurity
Product recalls
FDA approval
Litigation
Supply chain

And 15 more.

ZBH

Litigation
Reimbursement
Tax
Goodwill impairment
Cybersecurity
Export controls

And 20 more.

Tracked managers holding both

Dodge & Cox Dodge & Cox 0.00% · 1.09%
Joel Greenblatt Gotham Asset Management 0.10% · 0.01%

Updated Sep 8, 2026 · the newer of the two companies' filings